Intensity Therapeutics, Inc. (INTS) shareholders
Close on Nov 11, 2026Market cap $10.71MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lewis H. Bender | 2,245,000 | 16.10% | 13G (passive) | Dec 31, 2023 |
| LFP Management, LLC | 745,872 | 5.40% | 13G (passive) | May 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INTS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kingsbury Capital Investment Advisors LLC | 496,493 | 15.21% | $2.04M | +458,439 | 1.72% |
| Kmt Wealth Management, LLC | 496,493 | 15.21% | $2.04M | New | 1.72% |
| Sentinus, LLC | 26,723 | 0.82% | $109.56K | +3,429 | 0.01% |
| Vanguard Capital Management LLC | 26,569 | 0.81% | $108.93K | +9,728 | 0.00% |
| Sapient Capital LLC | 26,006 | 0.80% | $106.63K | – | 0.00% |
| Nano Cap New Millennium Growth Fund L P | 25,000 | 0.77% | $102.50K | – | 0.08% |
| Geode Capital Management, LLC | 22,787 | 0.70% | $93.43K | −3,232 | 0.00% |
| FNY Investment Advisers, LLC | 22,000 | 0.67% | $90.00K | New | 0.03% |
| Mesirow Financial Investment Management, Inc. | 14,118 | 0.43% | $57.88K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 9,121 | 0.28% | $37.40K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 1,984 | 0.06% | $8.13K | +1,917 | 0.00% |
| NewEdge Advisors, LLC | 1,148 | 0.04% | $4.71K | – | 0.00% |
| Osaic Holdings, Inc. | 200 | 0.01% | $820 | – | 0.00% |
| Barclays PLC | 42 | 0.00% | $172 | New | 0.00% |
| Morgan Stanley | 20 | 0.00% | $82 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 6 | 0.00% | $25 | New | 0.00% |
| UBS Group AG | 1 | 0.00% | $4 | −191 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 17 | 1M | 35.8% | 4 / 4 | 2 / 1 | 1M | 0M |
| Q1 2026 | 14 | 0M | 5.5% | 14 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held INTS in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INTS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 26,569 | 0.81% | $108.93K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 13,588 | 0.42% | $59.65K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 3,245 | 0.10% | $14.25K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 3,092 | 0.09% | $13.57K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 276 | 0.01% | $1.21K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lewis H. Bender | President and CEO, Director | 118,549 | 3.63% | Jul 20, 2026 |
| Joseph Talamo | Chief Financial Officer | 2,239 | 0.07% | Jul 20, 2026 |
| John M. Wesolowski | Principal Accounting Officer | 7,102 | 0.22% | Jul 20, 2026 |
| Thomas I. H. Dubin | Director | – | – | Jul 20, 2026 |
| Mark A. Goldberg | Director | – | – | Jul 20, 2026 |
| Daniel Donovan | Director | – | – | Jul 20, 2026 |
| Emer Leahy | Director | – | – | Jul 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John M. Wesolowski Principal Accounting Officer | Jun 30, 2026 | Award | +3,688 | $3.49 | $12.87K | 7,102 |
| Joseph Talamo Chief Financial Officer | Jun 30, 2026 | Award | +1,093 | $3.49 | $3.81K | 2,239 |
| Lewis H. Bender President and CEO, Director | Mar 26, 2026 | Award | +37,749 | $6.11 | $230.65K | 118,549 |
| Joseph Talamo Chief Financial Officer | Dec 31, 2025 | Award | +14,482 | $0.26 | $3.77K | 28,661 |
| John M. Wesolowski Principal Accounting Officer | Dec 31, 2025 | Award | +8,918 | $0.26 | $2.32K | 85,354 |
| John M. Wesolowski Principal Accounting Officer | Jun 30, 2025 | Award | +69,745 | $0.26 | $18.13K | 76,436 |
| Joseph Talamo Chief Financial Officer | Jun 30, 2025 | Award | +14,179 | $0.26 | $3.69K | 14,179 |
| John M. Wesolowski Principal Accounting Officer | Jun 5, 2024 | Option exercise | +1,000 | $4.00 | $4.00K | 6,691 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Intensity Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,372 shares on Aug 28, 2026 over the last 90 days.
See a number that looks wrong?